AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Elekta

Capital/Financing Update Mar 9, 2015

2906_rns_2015-03-09_ea341c98-6b08-4cd1-bcb5-669ad0766564.pdf

Capital/Financing Update

Open in Viewer

Opens in native device viewer

Elekta establishes bond program

STOCKHOLM, March 9 – The Swedish Financial Supervisory Authority (Finansinspektionen) has today approved Elekta's (EKTA-B.ST) prospectus as part of Elekta's establishment of a Medium Term Note (MTN) Program, with a limit of SEK 5 billion.

Elekta AB (publ) is the issuer of the MTN Program, which enables issuing of bonds on the Swedish market.

"Effective financing is an important part in the continued implementation of our strategic agenda and continued growth. The bond program gives us a broader opportunity to diversify our funding," says Håkan Bergström, CFO.

The prospectus is available on Elekta's website www.elekta.com and will be available at www.finansinspektionen.se.

Elekta has appointed Skandinaviska Enskilda Banken (SEB) as lead manager and SEB, together with Danske Bank, as the issuing agent.

#

For further information, please contact: Håkan Bergström, CFO, Elekta AB Tel: +46 8 587 25 547, e-mail: [email protected] Time zone: CET: Central European Time

Tobias Bülow, Director Financial Communication, Elekta AB Tel: +46 722 215 017, e-mail: [email protected] Time zone: CET: Central European Time

The information was published at 16:00 CET on March 9, 2015.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resourceefficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.

Talk to a Data Expert

Have a question? We'll get back to you promptly.